HIFU

New blood test better at predicting prostate cancer risk than PSA

A new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By identifying molecular changes in the PSA protein, the findings of this study suggest that once validated, use of IsoPSA may reduce the need for biopsy, and may lower the likelihood of overdetection and overtreatment of nonlethal prostate cancer. A team of researchers from Cleveland Clinic, Louis Stokes Cleveland VA Medical Center, Kaiser Permanente Northwest, and other clinical sites have demonstrated that a new blood test known as IsoPSA detects prostate cancer more precisely than current tests in two crucial measures -- distinguishing cancer from benign conditions, and identifying patients with high-risk disease. By [...]

2017-12-13T13:37:20+00:00 May 16th, 2017|

Focused ultrasound therapy is here: Are you ready?

A new, highly disruptive therapeutic technology called focused ultrasound is transforming – standards of care around the globe. Published by Neal Kassell on LinkedIn Distinguished Professor of Neurosurgery at University of Virginia In this series, we asked speakers at the Milken Institute Global Conference to answer: How does one build a meaningful life in the age of technological disruption? Join the conversation by writing your own article here and including #MIGlobal. A new, highly disruptive therapeutic technology called focused ultrasound is slowly but definitively influencing – and on the verge of transforming – standards of care around the globe. This game-changing, noninvasive treatment option for a wide variety of serious medical disorders has the potential to be an alternative or adjunct to surgery, radiation therapy, drug delivery, [...]

2017-12-13T13:37:20+00:00 May 4th, 2017|

Study reveals genetic connection to aggressive prostate cancer

An international study published in the Journal of the National Cancer Institute has identified a genetic connection to the aggressive form of prostate cancer. The study showed a threefold increase in the risk of aggressive prostate cancer for men with the genetic mutation. The frequency of the gene variants varied from 6 to 14% of the population of men with prostate cancer. Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment/ prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld-Tanenbaum Research Institute. The study was led by Dr. Alexandre Zlotta, Director of Uro-Oncology at Mount Sinai Hospital, [...]

2017-12-13T13:37:20+00:00 March 21st, 2017|

Dr. Michael Lazar Offers Free HIFU Presentation Online

Dr. Michael Lazar of California HIFU recently gave a presentation in Santa Rosa discussing the benefits of high-intensity focused ultrasound for prostate cancer and now offers the presentation online. A public presentation recently held in Santa Rosa for a group gathered to learn more about high-intensity focused ultrasound (HIFU) provided an overview of how this exciting new prostate cancer treatment works, and included comparisons to other treatment options, as well as HIFU patient outcomes. The event also offered people a chance to meet Dr. Lazar who is a four-time board certified urologist and prostate cancer specialist providing HIFU to patients in California. It also gave attendees a chance to learn more prostate cancer and to ask important questions. During the presentation, Dr. Lazar discussed how [...]

2017-12-13T13:37:21+00:00 March 6th, 2017|

New discovery may lead to blood test predicting and preventing prostate cancer spread

University of Adelaide researchers have uncovered a new pathway which regulates the spread of prostate cancer around the body. Published in the journal Cancer Research, the discovery has potential to lead to the development of a blood test that could predict whether cancer will spread from the prostate tumour to other parts of the body. The research also reveals potential new targets for drugs that may inhibit the spread of cancer. "Prostate cancers only kill men after they have spread or 'metastasised' from the prostate," says project leader Dr Luke Selth, Senior Research Fellow at the University of Adelaide's Dame Roma Mitchell Cancer Research Laboratories and a member of the Freemasons Foundation Centre for Men's Health. "The identification of markers that accurately predict, at an [...]

2017-02-21T08:57:11+00:00 February 21st, 2017|

Free HIFU Info Session Scheduled for February

Do you have prostate cancer? There is now a non-invasive treatment option. Join Dr. Michael Lazar of California HIFU for a special Prostate Cancer Treatment Information session scheduled for Thurs., Feb. 16, 2017 at 7 p.m. This free session will be held at the Friedman Event Center, 4676 Mayette Ave., Santa Rosa, CA 95405. Dr. Lazar will discuss how Sonablate HIFU can treat Prostate Cancer with lower risk of side effects such as impotence and incontinence. HIFU is radiation free - provides quick recovery - requires no chemotherapy and no surgery. Free and open to the public. Call for reservations today Jennifer Radovich 707-546-5553. Refreshments will be provided. Brought to you by HIFU Prostate Services and California HIFU.

2017-12-13T13:37:21+00:00 January 31st, 2017|

Prostate Cancer Rates Take a Nose Dive Per Latest Statistics

Dr. Michael Lazar of California HIFU, Urologist and Prostate Cancer expert reflects on the latest American Cancer Society statics The results from the American Cancer Society’s newest report on cancer rates is good news for everyone and particularly good news for prostate cancer patients: incidents of cancer is down as is the likelihood of prostate cancer patients dying from the diagnosis. According to the report the cancer death rate has dropped from its peak of 215.1 in 1991 to 161.2 in 2014 (per 100K population), the most recent year for which data was available to analyze. Overall the decline in cancer is linked with decreases in smoking and advances in early detection and treatment. The four major cancer drops are: lung (- 43% between 1990 [...]

2017-06-07T08:43:49+00:00 January 23rd, 2017|

Researchers unravel genetic codes to determine why inherited prostate cancer is so deadly

Prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years. The findings, published online in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated [...]

2017-12-13T13:37:21+00:00 January 10th, 2017|

Sonablate HIFU Tissue Change Monitoring

HIFU, which stands for high intensity focused ultrasound is a recently approved new technology for prostate tissue ablation. Many urologists have worked with HIFU for several years to offer their patients a minimally invasive treatment option for prostate cancer, either as a part of a clinical trial or at international treatment centers outside the United States. There are currently two different medical devices that use HIFU energy to heat and destroy tissue in the prostate. The most technologically advanced HIFU device for prostate cancer is called the Sonablate. The Sonablate is a software directed device that includes a computer console, a transrectal probe and a chilling unit. The Sonablate software that physicians use to plan and execute Sonablate HIFU treatment has state-of-the-art features that make [...]

2017-12-13T13:37:21+00:00 December 20th, 2016|

New study suggests a more accurate system for early detection, treatment of prostate cancer

A new study may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. It’s a promising development given prostate cancer is the second most common cancer among men worldwide, responsible for 308,000 deaths in 2012 and estimated to take 26,120 lives in the U.S. alone in 2016. New research coauthored by Brigham Young University researchers may lead to a more accurate system for early detection, diagnosis, and treatment of prostate cancer. The new study, published this week in Proceedings of the National Academy of Sciences, details a computer model that uses medical images to reproduce the growth patterns of prostate cancer on the anatomy of a patient's prostate. This type of mathematical modeling and simulation of disease (aka predictive [...]

2017-12-13T13:37:21+00:00 December 6th, 2016|